RESEARCHER PROFILE
Markus Hinder
← Back to Hochschule Fresenius
M
Hochschule Fresenius
Markus Hinder works in Pharmaceutical Economics and Policy, Pharmaceutical industry and healthcare, Blood Pressure and Hypertension Studies, Renin-Angiotensin System Studies, Computational Drug Discovery Methods. Recorded institutional associations include Novartis (Switzerland), University of Zurich, Hochschule Fresenius.
88Publications
1,823Citations
24H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Changing R&D models in research-based pharmaceutical companies
2016 · 286 citationsEffects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension
2016 · 143 citationsTranslational precision medicine: an industry perspective
2021 · 140 citationsThe effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects
2015 · 110 citationsAnalysis of pharma R&D productivity – a new perspective needed
2023 · 88 citationsLLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia
2021 · 72 citationsOpen innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
2018 · 68 citationsThe upside of being a digital pharma player
2020 · 62 citationsLicogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial
2021 · 57 citationsR&D efficiency of leading pharmaceutical companies – A 20-year analysis
2021 · 53 citationsOpen innovation: A paradigm shift in pharma R&D?
2022 · 48 citationsSafety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies
2025 · 47 citationsRole of Renal Nerves in the Stimulation of the Renin System by Reduced Renal Arterial Pressure
1999 · 44 citationsPost-translational Serine/Threonine Phosphorylation and Lysine Acetylation: A Novel Regulatory Aspect of the Global Nitrogen Response Regulator GlnR in S. coelicolor M145
2016 · 43 citationsBenchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022)
2025 · 42 citationsT‐type and L‐type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats
1998 · 36 citationsBig Techs and startups in pharmaceutical R&D – A 2020 perspective on artificial intelligence
2021 · 33 citationsInvestigating the origins of recent pharmaceutical innovation
2023 · 33 citationsPharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure
2006 · 30 citationsUse of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid
2007 · 28 citationsPharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects
2016 · 27 citationsDirect and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease
2006 · 26 citationsThe significance of blockbusters in the pharmaceutical industry
2022 · 26 citationsIn vitroand clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696)
2016 · 24 citationsEffect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide
2010 · 23 citations
